Study analysis · Oncotarget · 2016
Low testosterone may signal aggressive prostate cancer in men choosing watchful waiting.
Men with low testosterone and low-risk prostate cancer are more likely to have aggressive cancer than their biopsies suggest.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked back at a group of men who had prostate surgery and found that those with low testosterone before surgery were more likely to have more aggressive cancer when the prostate was checked after removal. But this doesn't prove that low testosterone caused the cancer to be worse; it might be that something else (like being overweight) caused both the low testosterone and the aggressive cancer. So we can only say they are connected, not that one causes the other.
What’s the bottom line?
This study looked at men with low-risk prostate cancer who were candidates for active surveillance (watching the cancer closely instead of treating it right away). They checked testosterone levels before surgery and found that men with low testosterone (<300 ng/dL) were more likely to have higher-grade or more advanced cancer than expected based on their initial biopsies.
How strong is this study?
The study was done pretty carefully: they had a good number of men, measured testosterone at the right time of day, and had experts look at the cancer without knowing the testosterone levels. But because it was a 'look back' study and not a controlled experiment, we have to be careful about trusting the results too much. Other differences between the men might have influenced the results.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
20 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=338)+16.3/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational retrospective design without randomization, no control group, potential unmeasured confounding (e.g., SHBG, free testosterone, metabolic factors), and inability to establish temporal sequence reliably. Cannot rule out reverse causation or common cause.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were declared in the provided text. The study appears to be independently conducted without apparent industry involvement.
The text excerpt lacks any conflict of interest declaration or funding statement. It is possible that these sections exist in the full article but were not included in the provided text.
Key takeaways
- 01
Men with low testosterone had a 2-3 times higher risk of having cancer that had spread beyond the prostate (upstaging) or was a more aggressive type (upgrading) after surgery.
- 02
For example, median testosterone was 400.5 ng/dL in those with upgrading vs 497.5 in those without, and 299.5 vs 488.5 for upstaging.
- 03
Yes, the differences were statistically significant and clinically meaningful.
- 04
The findings suggest that measuring testosterone could help identify which low-risk patients might actually have more dangerous cancer and need immediate treatment rather than active surveillance.
Surprising findings
- Low testosterone is associated with worse outcomes in low-risk prostate cancer, contrary to the historical belief that low testosterone protects against prostate cancer.For decades, testosterone was thought to fuel prostate cancer growth, leading to androgen deprivation therapy. This study flips that idea, showing low T may actually indicate more aggressive disease.
- Testosterone improved predictive accuracy by up to 15% for upstaging, but not for upgrading or unfavorable disease.One might expect testosterone to predict all adverse outcomes equally, but it was specifically better at predicting cancer stage (upstaging) rather than grade (upgrading) or combined unfavorable disease.
Practical takeaways
If you're a man considering active surveillance for low-risk prostate cancer, ask your doctor to check your total testosterone level.
This study is retrospective and used a single testosterone measurement. Confirmatory testing with free testosterone, SHBG, and possibly mass spectrometry is recommended before changing clinical decisions.
medium confidenceMen with testosterone <300 ng/dL may benefit from more aggressive monitoring (e.g., more frequent PSA tests, multiparametric MRI) or reconsidering active surveillance.
The study did not assess outcomes like biochemical recurrence or cancer-specific mortality. Long-term benefits of altering management based on testosterone are unknown.
medium confidenceClinicians should consider including testosterone in risk models for low-risk prostate cancer, as it improved upstaging prediction by 12-15%.
The improvement was only significant for upstaging, not upgrading or unfavorable disease. It should be used alongside existing criteria, not replace them.
medium confidenceWhy this study matters
Testosterone: A missing piece in active surveillance?
In 338 low-risk prostate cancer patients eligible for active surveillance, those with total testosterone below 300 ng/dL had significantly higher rates of upstaging (stage >pT2) and upgrading (Gleason ≥7 with primary pattern 4). For example, median testosterone in upstaged patients was 299.5 ng/dL vs. 488.5 in non-upstaged (p<0.001). Adding testosterone to standard models improved prediction of upstaging by 12-15%.
Active surveillance spares men from treatment side effects, but up to 30% may have more aggressive disease than initially thought. Testosterone could be a simple, cheap blood test to better select candidates.
Low T linked to positive surgical margins
Hypogonadal men (testosterone <300 ng/dL) had nearly double the rate of positive surgical margins after prostatectomy (27.8% vs. 14.2%, p=0.035). Positive margins indicate cancer cells left behind, increasing recurrence risk.
This suggests low testosterone may lead to more aggressive or invasive tumors that are harder to remove completely, affecting surgical planning.
Optimal testosterone cutoff: 344 ng/dL
ROC analysis identified 344 ng/dL as the best threshold for predicting upstaging, with an AUC of 0.81 (95% CI 0.75-0.88). This means it correctly identifies 81% of cases. The commonly used hypogonadism cutoff of 300 ng/dL also performed well.
Doctors often consider 300 ng/dL as low, but this study suggests a slightly higher cutoff may be more predictive for prostate cancer aggressiveness.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at men with low-risk prostate cancer who were candidates for active surveillance (watching the cancer closely instead of treating it right away). They checked testosterone levels before surgery and found that men with low testosterone (<300 ng/dL) were more likely to have higher-grade or more advanced cancer than expected based on their initial biopsies.
Research results
Men with low testosterone had a 2-3 times higher risk of having cancer that had spread beyond the prostate (upstaging) or was a more aggressive type (upgrading) after surgery. For example, median testosterone was 400.5 ng/dL in those with upgrading vs 497.5 in those without, and 299.5 vs 488.5 for upstaging.
What this means - more context
Yes, the differences were statistically significant and clinically meaningful. The findings suggest that measuring testosterone could help identify which low-risk patients might actually have more dangerous cancer and need immediate treatment rather than active surveillance.
To evaluate the association of serum total testosterone levels with pathological reclassification (upstaging, upgrading, unfavorable disease) in low-risk prostate cancer patients eligible for active surveillance who underwent radical prostatectomy.
In 338 low-risk prostate cancer patients meeting active surveillance criteria, low serum total testosterone (<300 ng/dL) was significantly associated with higher rates of pathological upstaging (stage >pT2), upgrading (Gleason score ≥7 with primary pattern 4), unfavorable disease, and positive surgical margins. Adding testosterone to a base model improved predictive accuracy for upstaging by 12-15%. The authors advocate using testosterone as a selection criterion for active surveillance.
Methods Used
Retrospective cohort study of 338 men with low-risk prostate cancer (clinical stage ≤T2a, PSA <10 ng/ml, Gleason ≤6, ≤2 positive cores, PSA density <0.2 ng/mL/cc) who underwent radical prostatectomy. Serum total testosterone was measured preoperatively. Pathological outcomes (upstaging, upgrading, unfavorable disease) were assessed. Multivariable logistic regression and ROC analysis were used.
Main Finding
Low serum total testosterone (<300 ng/dL) is an independent predictor of pathological upstaging (stage >pT2) and upgrading (Gleason ≥7 with primary pattern 4) in low-risk prostate cancer patients eligible for active surveillance, with a testosterone threshold of 344 ng/dL providing optimal sensitivity/specificity for upstaging (AUC 0.81).
Confidence Level
Moderate - retrospective design, lack of free/bioavailable testosterone and SHBG measurements, no mass spectrometry, no long-term outcomes, but large sample size and standardized testosterone assay.
Study Flags
Red Flags
- •Retrospective design - cannot establish causality
- •Single testosterone measurement - subject to variability
- •No free or bioavailable testosterone, SHBG, or mass spectrometry data
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Low testosterone is associated with worse outcomes in low-risk prostate cancer, contrary to the historical belief that low testosterone protects against prostate cancer.
For decades, testosterone was thought to fuel prostate cancer growth, leading to androgen deprivation therapy. This study flips that idea, showing low T may actually indicate more aggressive disease.
Practical Takeaways
If you're a man considering active surveillance for low-risk prostate cancer, ask your doctor to check your total testosterone level.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked back at a group of men who had prostate surgery and found that those with low testosterone before surgery were more likely to have more aggressive cancer when the prostate was checked after removal. But this doesn't prove that low testosterone caused the cancer to be worse; it might be that something else (like being overweight) caused both the low testosterone and the aggressive cancer. So we can only say they are connected, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Large sample for a single cohort study (n=338).
- Standardized hormone assay with morning collections.
- Blinded pathology review by experienced uropathologists.
Weaknesses
- Retrospective design.
- No control group (e.g., men on active surveillance without surgery).
- No measurement of free testosterone, SHBG, or other hormones.
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at men with low-risk prostate cancer who were candidates for active surveillance (watching the cancer closely instead of treating it right away). They checked testosterone levels before surgery and found that men with low testosterone (<300 ng/dL) were more likely to have higher-grade or more advanced cancer than expected based on their initial biopsies.
Research results
Men with low testosterone had a 2-3 times higher risk of having cancer that had spread beyond the prostate (upstaging) or was a more aggressive type (upgrading) after surgery. For example, median testosterone was 400.5 ng/dL in those with upgrading vs 497.5 in those without, and 299.5 vs 488.5 for upstaging.
What this means - more context
Yes, the differences were statistically significant and clinically meaningful. The findings suggest that measuring testosterone could help identify which low-risk patients might actually have more dangerous cancer and need immediate treatment rather than active surveillance.
To evaluate the association of serum total testosterone levels with pathological reclassification (upstaging, upgrading, unfavorable disease) in low-risk prostate cancer patients eligible for active surveillance who underwent radical prostatectomy.
In 338 low-risk prostate cancer patients meeting active surveillance criteria, low serum total testosterone (<300 ng/dL) was significantly associated with higher rates of pathological upstaging (stage >pT2), upgrading (Gleason score ≥7 with primary pattern 4), unfavorable disease, and positive surgical margins. Adding testosterone to a base model improved predictive accuracy for upstaging by 12-15%. The authors advocate using testosterone as a selection criterion for active surveillance.
Methods Used
Retrospective cohort study of 338 men with low-risk prostate cancer (clinical stage ≤T2a, PSA <10 ng/ml, Gleason ≤6, ≤2 positive cores, PSA density <0.2 ng/mL/cc) who underwent radical prostatectomy. Serum total testosterone was measured preoperatively. Pathological outcomes (upstaging, upgrading, unfavorable disease) were assessed. Multivariable logistic regression and ROC analysis were used.
Main Finding
Low serum total testosterone (<300 ng/dL) is an independent predictor of pathological upstaging (stage >pT2) and upgrading (Gleason ≥7 with primary pattern 4) in low-risk prostate cancer patients eligible for active surveillance, with a testosterone threshold of 344 ng/dL providing optimal sensitivity/specificity for upstaging (AUC 0.81).
Confidence Level
Moderate - retrospective design, lack of free/bioavailable testosterone and SHBG measurements, no mass spectrometry, no long-term outcomes, but large sample size and standardized testosterone assay.
Study Flags
Red Flags
- •Retrospective design - cannot establish causality
- •Single testosterone measurement - subject to variability
- •No free or bioavailable testosterone, SHBG, or mass spectrometry data
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Surprising Findings
Low testosterone is associated with worse outcomes in low-risk prostate cancer, contrary to the historical belief that low testosterone protects against prostate cancer.
For decades, testosterone was thought to fuel prostate cancer growth, leading to androgen deprivation therapy. This study flips that idea, showing low T may actually indicate more aggressive disease.
Practical Takeaways
If you're a man considering active surveillance for low-risk prostate cancer, ask your doctor to check your total testosterone level.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked back at a group of men who had prostate surgery and found that those with low testosterone before surgery were more likely to have more aggressive cancer when the prostate was checked after removal. But this doesn't prove that low testosterone caused the cancer to be worse; it might be that something else (like being overweight) caused both the low testosterone and the aggressive cancer. So we can only say they are connected, not that one causes the other.
The study has a COI section but no disclosure was found. A small penalty has been applied.
Strengths
- Large sample for a single cohort study (n=338).
- Standardized hormone assay with morning collections.
- Blinded pathology review by experienced uropathologists.
Weaknesses
- Retrospective design.
- No control group (e.g., men on active surveillance without surgery).
- No measurement of free testosterone, SHBG, or other hormones.
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study was done pretty carefully: they had a good number of men, measured testosterone at the right time of day, and had experts look at the cancer without knowing the testosterone levels. But because it was a 'look back' study and not a controlled experiment, we have to be careful about trusting the results too much. Other differences between the men might have influenced the results.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
20 / 100
- Randomizationnot randomized
- Blindingnot blinded
- Control groupno control group
- Sample size (n=338)+16.3/20
- Follow-upno follow-up reported
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 554 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Observational retrospective design without randomization, no control group, potential unmeasured confounding (e.g., SHBG, free testosterone, metabolic factors), and inability to establish temporal sequence reliably. Cannot rule out reverse causation or common cause.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding information were declared in the provided text. The study appears to be independently conducted without apparent industry involvement.
The text excerpt lacks any conflict of interest declaration or funding statement. It is possible that these sections exist in the full article but were not included in the provided text.